MARKET

BIVI

BIVI

Biovie Inc
NASDAQ
1.100
+0.030
+2.80%
After Hours: 1.119 +0.019 +1.70% 19:41 05/14 EDT
OPEN
1.070
PREV CLOSE
1.070
HIGH
1.130
LOW
1.050
VOLUME
455.06K
TURNOVER
--
52 WEEK HIGH
7.50
52 WEEK LOW
0.6200
MARKET CAP
20.42M
P/E (TTM)
-0.2776
1D
5D
1M
3M
1Y
5Y
1D
BioVie to host KOL event on Phase 2 study of bezisterim
TipRanks · 12h ago
Weekly Report: what happened at BIVI last week (0505-0509)?
Weekly Report · 2d ago
BioVie to present design of Phase 2 SUNRISE-PD trial
TipRanks · 05/07 12:24
BioVie Announces It Will Present Rationale And Design of Phase 2 SUNRISE-PD Clinical Trial At 30th World Congress On Parkinson's Disease And Related Disorders May 7-10, 2025 In New York City
Benzinga · 05/07 12:02
Biotech Alert: Searches spiking for these stocks today
TipRanks · 05/05 16:11
BioVie announces formation of Corporate Advisory Board
TipRanks · 05/05 12:27
Press Release: BioVie Unveils Corporate Advisory Board Featuring Neuralink Co-Founder, Former Executives from Mastercard and Apple, and High-Impact Industry Leaders to Advance BioVie Mission and Growth
Dow Jones · 05/05 12:00
Press Release: BioVie Unveils Corporate Advisory -2-
Dow Jones · 05/05 12:00
More
About BIVI
More
BioVie Inc. is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders. In neurodegenerative disease, the Company’s drug candidate bezisterim (NE3107) inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not extracellular single-regulated kinase (ERK) and nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB) homeostatic functions (insulin signaling and neuron growth and survival). Both inflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). In liver disease, its orphan drug candidate BIV201 (continuous infusion terlipressin) is in the phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites.
Recently
Symbol
Price
%Change

Webull offers BioVie Inc stock information, including NASDAQ: BIVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BIVI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BIVI stock methods without spending real money on the virtual paper trading platform.